Glucocorticoids: The Debate Continues Déjà vu … In past decades, rheumatologists have seen, heard, practiced and taught much of what has been argued in the “ongoing debate” on the use of glucocorticoids (GCs) in the management of rheumatoid arthritis (RA).1 It is heartening to note that eminent professors have stuck to their premise all these…
Biosimilar for Infliximab Launched in Europe
Plus, updates on arhalofenate, ALO-02, and other rheumatology drug news, safety information
Certolizumab Pegol Drug Studies Find No New Safety Issues
Plus, updates on clazakizumab, hydrocodone bitartrate extended-release capsules and other rheumatology drug news, safety information
Drug Interactions for Trimethoprim/ Sulfamethoxazole Come to Light
Plus, updates on buprenorphine, diclofenac sodium, secukinumab and other rheumatology drug news, safety information
2014 ACR/ARHP Annual Meeting: Rheumatology Drug Updates, Safety News
Plus, hydrocodone combination products and brodalumab
Commentary: Generic Drugs Can Increase Opportunities for Medication Errors
Why dispensing pharmacies should provide color chart of generic drugs they substitute each month
Hepatitis Reaction with Rituximab Sparks Drug Safety Alert
The FDA modifies rituximab prescribing information to stress risk of hepatitis B virus reactivation
Chikungunya: What Every Rheumatologist Needs to Know
How to spot, diagnose and treat this rapidly spreading mosquito-borne viral illness whose symptoms mimic arthritis
HIPAA Privacy Rules Bring New Enforcement Guidelines
Focus shifts from voluntary to punitive; makes business associates more accountable for breaches of personal health information
Are Insurance Companies’ Medication Directives Fiscally, Medically Questionable?
A reader questions whether insurers’ practice of promoting medications has undermined physicians’ ability to provide quality patient care
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 13
- Next Page »